Literature DB >> 21761566

Unexpected opioid activity profiles of analogues of the novel peptide kappa opioid receptor ligand CJ-15,208.

Jane V Aldrich1, Santosh S Kulkarni, Sanjeewa N Senadheera, Nicolette C Ross, Kate J Reilley, Shainnel O Eans, Michelle L Ganno, Thomas F Murray, Jay P McLaughlin.   

Abstract

An alanine scan was performed on the novel κ opioid receptor (KOR) peptide ligand CJ-15,208 to determine which residues contribute to the potent in vivo agonist activity observed for the parent peptide. These cyclic tetrapeptides were synthesized by a combination of solid-phase peptide synthesis of the linear precursors, followed by cyclization in solution. Like the parent peptide, each of the analogues exhibited agonist activity and KOR antagonist activity in an antinociceptive assay in vivo. Unlike the parent peptide, the agonist activity of the potent analogues was mediated predominantly, if not exclusively, by μ opioid receptors (MOR). Thus analogues 2 and 4, in which one of the phenylalanine residues was replaced by alanine, exhibited both potent MOR agonist activity and KOR antagonist activity in vivo. These peptides represent novel lead compounds for the development of peptide-based opioid analgesics.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21761566      PMCID: PMC3667675          DOI: 10.1002/cmdc.201100113

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  37 in total

1.  Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse.

Authors:  T J HALEY; W G MCCORMICK
Journal:  Br J Pharmacol Chemother       Date:  1957-03

2.  Hydrostatic pressure alters the time course of GTP

Authors: 
Journal:  Biol Bull       Date:  1999-12       Impact factor: 1.818

3.  An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence.

Authors:  R B Rothman; D A Gorelick; S J Heishman; P R Eichmiller; B H Hill; J Norbeck; J G Liberto
Journal:  J Subst Abuse Treat       Date:  2000-04

4.  Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity.

Authors:  J P McLaughlin; K P Hill; Q Jiang; A Sebastian; S Archer; J M Bidlack
Journal:  J Pharmacol Exp Ther       Date:  1999-04       Impact factor: 4.030

5.  Antinociceptive and respiratory effects of intrathecal H-Tyr-D-Arg-Phe-Lys-NH2 (DALDA) and [Dmt1] DALDA.

Authors:  M Shimoyama; N Shimoyama; G M Zhao; P W Schiller; H H Szeto
Journal:  J Pharmacol Exp Ther       Date:  2001-04       Impact factor: 4.030

6.  Differential antinociceptive effects induced by intrathecally administered endomorphin-1 and endomorphin-2 in the mouse.

Authors:  S Sakurada; T Hayashi; M Yuhki; T Orito; J E Zadina; A J Kastin; T Fujimura; K Murayama; C Sakurada; T Sakurada; M Narita; T Suzuki; K Tan-no; L F Tseng
Journal:  Eur J Pharmacol       Date:  2001-09-21       Impact factor: 4.432

7.  Naltrexone and buprenorphine combination in the treatment of opioid dependence.

Authors:  G Gerra; A Fantoma; A Zaimovic
Journal:  J Psychopharmacol       Date:  2006-01-09       Impact factor: 4.153

8.  Synthesis and opioid activity of conformationally constrained dynorphin A analogues. 2. Conformational constraint in the "address" sequence.

Authors:  S Arttamangkul; J E Ishmael; T F Murray; D K Grandy; G E DeLander; B L Kieffer; J V Aldrich
Journal:  J Med Chem       Date:  1997-04-11       Impact factor: 7.446

9.  Effects of JDTic, a selective kappa-opioid receptor antagonist, on the development and expression of physical dependence on morphine using a rat continuous-infusion model.

Authors:  F Ivy Carroll; Louis S Harris; Mario D Aceto
Journal:  Eur J Pharmacol       Date:  2005-10-19       Impact factor: 4.432

10.  CJ-15,208, a novel kappa opioid receptor antagonist from a fungus, Ctenomyces serratus ATCC15502.

Authors:  Toshiyuki Saito; Hideo Hirai; Yoon-Jeong Kim; Yasuhiro Kojima; Yasue Matsunaga; Hiroyuki Nishida; Tatsuo Sakakibara; Osamu Suga; Tetsujo Sujaku; Nakao Kojima
Journal:  J Antibiot (Tokyo)       Date:  2002-10       Impact factor: 2.649

View more
  15 in total

1.  Design, synthesis, and opioid activity of arodyn analogs cyclized by ring-closing metathesis involving Tyr(allyl).

Authors:  Wei-Jie Fang; Thomas F Murray; Jane V Aldrich
Journal:  Bioorg Med Chem       Date:  2017-11-21       Impact factor: 3.641

2.  Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2.

Authors:  András Váradi; Gina F Marrone; Travis C Palmer; Ankita Narayan; Márton R Szabó; Valerie Le Rouzic; Steven G Grinnell; Joan J Subrath; Evelyn Warner; Sanjay Kalra; Amanda Hunkele; Jeremy Pagirsky; Shainnel O Eans; Jessica M Medina; Jin Xu; Ying-Xian Pan; Attila Borics; Gavril W Pasternak; Jay P McLaughlin; Susruta Majumdar
Journal:  J Med Chem       Date:  2016-09-02       Impact factor: 7.446

3.  Alanine analogues of [D-Trp]CJ-15,208: novel opioid activity profiles and prevention of drug- and stress-induced reinstatement of cocaine-seeking behaviour.

Authors:  J V Aldrich; S N Senadheera; N C Ross; K A Reilley; M L Ganno; S E Eans; T F Murray; J P McLaughlin
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

4.  The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine-seeking behavior.

Authors:  Jane V Aldrich; Sanjeewa N Senadheera; Nicolette C Ross; Michelle L Ganno; Shainnel O Eans; Jay P McLaughlin
Journal:  J Nat Prod       Date:  2013-01-17       Impact factor: 4.050

Review 5.  Development of κ opioid receptor antagonists.

Authors:  F Ivy Carroll; William A Carlezon
Journal:  J Med Chem       Date:  2013-02-14       Impact factor: 7.446

Review 6.  Cyclic Opioid Peptides.

Authors:  Michael Remesic; Yeon Sun Lee; Victor J Hruby
Journal:  Curr Med Chem       Date:  2016       Impact factor: 4.530

7.  Optimized Ring Closing Metathesis Reaction Conditions To Suppress Desallyl Side Products in the Solid-Phase Synthesis of Cyclic Peptides Involving Tyrosine(O-allyl).

Authors:  Solomon A Gisemba; Jane V Aldrich
Journal:  J Org Chem       Date:  2020-01-13       Impact factor: 4.354

8.  Development of a robust, sensitive and selective liquid chromatography-tandem mass spectrometry assay for the quantification of the novel macrocyclic peptide kappa opioid receptor antagonist [D-Trp]CJ-15,208 in plasma and application to an initial pharmacokinetic study.

Authors:  Tanvir Khaliq; Todd D Williams; Sanjeewa N Senadheera; Jane V Aldrich
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2016-06-02       Impact factor: 3.205

9.  Naturally Inspired Peptide Leads: Alanine Scanning Reveals an Actin-Targeting Thiazole Analogue of Bisebromoamide.

Authors:  Heather J Johnston; Sarah K Boys; Ashraff Makda; Neil O Carragher; Alison N Hulme
Journal:  Chembiochem       Date:  2016-08-05       Impact factor: 3.164

10.  Cyclic Peptoid-Peptide Hybrids as Versatile Molecular Transporters.

Authors:  Claudine Nicole Herlan; Anna Meschkov; Ute Schepers; Stefan Bräse
Journal:  Front Chem       Date:  2021-06-25       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.